Arrowhead Pharmaceuticals, Inc. (0HI3.L)
USD 21.69
(-2.58%)
USD 21.69
(-2.58%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 445.73 Million USD | 5.69% |
| 2022 | 421.73 Million USD | 46.78% |
| 2021 | 287.32 Million USD | 58.61% |
| 2020 | 181.15 Million USD | 68.35% |
| 2019 | 107.6 Million USD | 49.29% |
| 2018 | 72.07 Million USD | 5.37% |
| 2017 | 68.4 Million USD | -14.34% |
| 2016 | 79.85 Million USD | -17.13% |
| 2015 | 96.35 Million USD | 87.91% |
| 2014 | 51.27 Million USD | 117.55% |
| 2013 | 23.57 Million USD | 11.0% |
| 2012 | 21.23 Million USD | 109.71% |
| 2011 | 10.12 Million USD | 7.47% |
| 2010 | 9.42 Million USD | -59.91% |
| 2009 | 23.5 Million USD | -35.27% |
| 2008 | 36.3 Million USD | -5.54% |
| 2007 | 38.43 Million USD | 76.01% |
| 2006 | 21.83 Million USD | 119.38% |
| 2005 | 9.95 Million USD | 235.68% |
| 2004 | 2.96 Million USD | 3039.83% |
| 2003 | 94.43 Thousand USD | -93.34% |
| 2002 | 1.41 Million USD | 1197.94% |
| 2001 | 109.28 Thousand USD | -17.22% |
| 2000 | 132.01 Thousand USD | 46.1% |
| 1999 | 90.36 Thousand USD | 31.17% |
| 1998 | 68.88 Thousand USD | -65.25% |
| 1997 | 198.23 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 171.35 Million USD | 44.77% |
| 2024 Q1 | 140.09 Million USD | 12.59% |
| 2024 Q2 | 121.66 Million USD | -13.16% |
| 2023 Q1 | 104.68 Million USD | -9.29% |
| 2023 Q2 | 98.1 Million USD | -6.28% |
| 2023 Q4 | 124.42 Million USD | 4.98% |
| 2023 FY | 445.73 Million USD | 5.69% |
| 2023 Q3 | 118.52 Million USD | 20.82% |
| 2022 Q4 | 115.4 Million USD | 9.57% |
| 2022 Q2 | 110.25 Million USD | 21.48% |
| 2022 Q1 | 90.76 Million USD | -12.03% |
| 2022 FY | 421.73 Million USD | 46.78% |
| 2022 Q3 | 105.32 Million USD | -4.47% |
| 2021 Q4 | 103.16 Million USD | 32.67% |
| 2021 FY | 287.32 Million USD | 58.61% |
| 2021 Q1 | 45.35 Million USD | -21.46% |
| 2021 Q2 | 61.04 Million USD | 34.58% |
| 2021 Q3 | 77.75 Million USD | 27.38% |
| 2020 Q3 | 43.32 Million USD | -5.35% |
| 2020 Q4 | 57.75 Million USD | 33.31% |
| 2020 Q2 | 45.76 Million USD | 33.41% |
| 2020 FY | 181.15 Million USD | 68.35% |
| 2020 Q1 | 34.3 Million USD | 1.94% |
| 2019 Q1 | 23.71 Million USD | 5.74% |
| 2019 Q3 | 24.1 Million USD | -7.79% |
| 2019 Q4 | 33.65 Million USD | 39.64% |
| 2019 Q2 | 26.13 Million USD | 10.23% |
| 2019 FY | 107.6 Million USD | 49.29% |
| 2018 Q3 | 16.64 Million USD | 6.14% |
| 2018 FY | 72.07 Million USD | 5.37% |
| 2018 Q4 | 22.42 Million USD | 34.7% |
| 2018 Q2 | 15.68 Million USD | -9.46% |
| 2018 Q1 | 17.32 Million USD | -8.65% |
| 2017 Q1 | 19.26 Million USD | -2.57% |
| 2017 FY | 68.4 Million USD | -14.34% |
| 2017 Q2 | 15.11 Million USD | -21.55% |
| 2017 Q4 | 18.96 Million USD | 25.95% |
| 2017 Q3 | 15.05 Million USD | -0.39% |
| 2016 Q3 | 19.38 Million USD | -9.05% |
| 2016 Q2 | 21.3 Million USD | 9.92% |
| 2016 Q4 | 19.77 Million USD | 2.04% |
| 2016 FY | 79.85 Million USD | -17.13% |
| 2016 Q1 | 19.38 Million USD | -23.3% |
| 2015 Q4 | 25.27 Million USD | 56.81% |
| 2015 FY | 96.35 Million USD | 87.91% |
| 2015 Q3 | 16.11 Million USD | -45.69% |
| 2015 Q2 | 29.67 Million USD | 17.36% |
| 2015 Q1 | 25.28 Million USD | 25.02% |
| 2014 Q1 | 7.05 Million USD | -12.31% |
| 2014 Q4 | 20.22 Million USD | 58.71% |
| 2014 Q3 | 12.74 Million USD | 13.22% |
| 2014 Q2 | 11.25 Million USD | 59.59% |
| 2014 FY | 51.27 Million USD | 117.55% |
| 2013 Q1 | 4.96 Million USD | -8.36% |
| 2013 Q2 | 5.43 Million USD | 9.36% |
| 2013 Q3 | 5.12 Million USD | -5.68% |
| 2013 Q4 | 8.04 Million USD | 56.92% |
| 2013 FY | 23.57 Million USD | 11.0% |
| 2012 Q1 | 4.06 Million USD | 39.49% |
| 2012 FY | 21.23 Million USD | 109.71% |
| 2012 Q4 | 5.42 Million USD | -20.85% |
| 2012 Q3 | 6.85 Million USD | 39.81% |
| 2012 Q2 | 4.9 Million USD | 20.6% |
| 2011 FY | 10.12 Million USD | 7.47% |
| 2011 Q1 | 6 Million USD | 137.42% |
| 2011 Q2 | 1.81 Million USD | -69.83% |
| 2011 Q3 | 1.77 Million USD | -2.29% |
| 2011 Q4 | 2.91 Million USD | 64.54% |
| 2010 Q3 | 2.29 Million USD | 0.49% |
| 2010 Q4 | 2.52 Million USD | 10.05% |
| 2010 FY | 9.42 Million USD | -59.91% |
| 2010 Q1 | 2.3 Million USD | -37.89% |
| 2010 Q2 | 2.28 Million USD | -0.93% |
| 2009 FY | 23.5 Million USD | -35.27% |
| 2009 Q4 | 3.71 Million USD | -25.03% |
| 2009 Q1 | 9.37 Million USD | -24.27% |
| 2009 Q2 | 5.45 Million USD | -41.85% |
| 2009 Q3 | 4.95 Million USD | -9.08% |
| 2008 Q4 | 12.38 Million USD | 24.18% |
| 2008 Q3 | 9.97 Million USD | 34.61% |
| 2008 Q2 | 7.4 Million USD | 6.42% |
| 2008 Q1 | 6.96 Million USD | -41.23% |
| 2008 FY | 36.3 Million USD | -5.54% |
| 2007 Q2 | 8.43 Million USD | 88.12% |
| 2007 Q1 | 4.48 Million USD | -49.03% |
| 2007 FY | 38.43 Million USD | 76.01% |
| 2007 Q4 | 11.84 Million USD | -13.38% |
| 2007 Q3 | 13.67 Million USD | 62.06% |
| 2006 FY | 21.83 Million USD | 119.38% |
| 2006 Q3 | 4.72 Million USD | 18.15% |
| 2006 Q1 | 4.3 Million USD | 89.55% |
| 2006 Q2 | 4 Million USD | -7.03% |
| 2006 Q4 | 8.79 Million USD | 86.06% |
| 2005 Q3 | 3.52 Million USD | 68.33% |
| 2005 Q2 | 2.09 Million USD | 0.2% |
| 2005 Q1 | 2.09 Million USD | 26.26% |
| 2005 FY | 9.95 Million USD | 235.68% |
| 2005 Q4 | 2.27 Million USD | -35.64% |
| 2004 Q2 | 388.93 Thousand USD | 172.9% |
| 2004 Q4 | 1.65 Million USD | 161.71% |
| 2004 Q1 | 142.52 Thousand USD | 848.0% |
| 2004 FY | 2.96 Million USD | 3039.83% |
| 2004 Q3 | 633.21 Thousand USD | 62.81% |
| 2003 Q3 | 15.29 Thousand USD | -49.55% |
| 2003 Q1 | 33.78 Thousand USD | -97.44% |
| 2003 FY | 94.43 Thousand USD | -93.34% |
| 2003 Q4 | 15.03 Thousand USD | -1.73% |
| 2003 Q2 | 30.32 Thousand USD | -10.24% |
| 2002 Q1 | 27.03 Thousand USD | 9.81% |
| 2002 FY | 1.41 Million USD | 1197.94% |
| 2002 Q4 | 1.31 Million USD | 2585.13% |
| 2002 Q3 | 49.13 Thousand USD | 113.92% |
| 2002 Q2 | 22.96 Thousand USD | -15.05% |
| 2001 Q4 | 24.62 Thousand USD | 31.92% |
| 2001 FY | 109.28 Thousand USD | -17.22% |
| 2001 Q2 | 25.61 Thousand USD | -36.55% |
| 2001 Q1 | 40.37 Thousand USD | 16.3% |
| 2001 Q3 | 18.66 Thousand USD | -27.14% |
| 2000 Q1 | 37.66 Thousand USD | 88.33% |
| 2000 FY | 132.01 Thousand USD | 46.1% |
| 2000 Q4 | 34.71 Thousand USD | 24.95% |
| 2000 Q2 | 31.85 Thousand USD | -15.44% |
| 2000 Q3 | 27.78 Thousand USD | -12.77% |
| 1999 Q3 | 230 Thousand USD | 1050.0% |
| 1999 FY | 90.36 Thousand USD | 31.17% |
| 1999 Q2 | 20 Thousand USD | 0.01% |
| 1999 Q1 | 19.99 Thousand USD | 0.0% |
| 1999 Q4 | 20 Thousand USD | -91.3% |
| 1998 Q2 | 20 Thousand USD | 0.0% |
| 1998 FY | 68.88 Thousand USD | -65.25% |
| 1998 Q3 | -10 Thousand USD | -150.0% |
| 1998 Q4 | 19.99 Thousand USD | 299.99% |
| 1997 FY | 198.23 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -164.633% |
| Codexis, Inc. | 66.51 Million USD | -570.1% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -74.961% |
| Organovo Holdings, Inc. | 14.91 Million USD | -2888.515% |